WuXi XDC Cayman Inc
2268
Rank in Stocks
#1886
WuXi XDC Cayman Inc. operates as an investment holding company and a global... WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company's expertise covers the entire lifecycle, from discovery and research to development and manufacturing, of biopharmaceutical products. Specifically, it focuses on antibody-drug conjugates (ADCs), various bioconjugates, monoclonal antibody intermediates, and the crucial payload-linkers integral to bioconjugate synthesis. Founded in 2013 and headquartered in Wuxi, China, WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc.
Share Price
$8.78
Market Cap
$11.12B
Change (1 day)
-9.52%
Change (1 year)
0.57%
Country
CN
Trade WuXi XDC Cayman Inc (2268)
Category
Healthcare
Revenue for WuXi XDC Cayman Inc (2268)
Revenue in Oct 2026 TTM: 0
According to WuXi XDC Cayman Inc latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for WuXi XDC Cayman Inc from 2020 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2025 | $849.61M | 53.03% |
| 2024 | $555.18M | 85.04% |
| 2023 | $300.04M | 108.96% |
| 2022 | $143.58M | 193.32% |
| 2021 | $48.95M | 231.89% |
| 2020 | $14.75M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $47.35B | - |
US
|
|
| $25.61B | - |
US
|
|
| $2.71B | - |
US
|
|
| - | - |
CN
|
|
| $7.37B | - |
US
|
